ABU DHABI, UAE — Thrombolytic treatment with recombinant human pro-urokinase was non-inferior to alteplase in achieving an excellent functional outcome in acute ischemic stroke but showed a ...
The registry data suggest improved outcomes without safety concerns, but confirmatory RCTs are needed, a researcher says.
Reteplase appears to be another safe and effective thrombolytic option for the treatment of acute ischemic stroke, according to results from the randomized RAISE trial. When given within the first 4.5 ...
Clot-busting drugs are the main treatment for stroke, but they have often not been recommended for people who have an aneurysm in their brains that has not ruptured. An aneurysm is a bulge in the wall ...
Thrombolytic drugs are the main treatment for stroke, but they have often not been recommended for people who have an aneurysm in their brains that has not ruptured. A new study (“Risk of Aneurysm ...
A research team led by Professor Shen Jiangang from the School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong (HKUMed) reveals that Angong Niuhuang Wan (AGNHW), a classical ...
The thrombolytic tenecteplase may have a role in reestablishing blood flow in patients with large-vessel acute ischemic stroke up to 24 hours after stroke onset selected by perfusion imaging, a new ...
(Reuters Health) - Not all U.S. stroke patients eligible for a clot-busting treatment actually receive it - and the odds of getting this therapy may depend on where they live, a large study finds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback